ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

roxadustat

Also written as “Roxadustat”, “FG-4592” and “ASP1517”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.

Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 201347 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma221 open or runningphase 3since Jun 25, 2013Sep 15, 2009Oct 30, 2027phase 3 · NCT05970172
Kyntra Bioits history only221 open or runningphase 4since Aug 8, 2019Sep 25, 2008Sep 2030phase 3 · NCT07722988
AstraZenecaits history only30 open or runningphase 4since Dec 3, 2020Jun 24, 2014none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Astellas Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Sep 15, 2009.

  1. Oct 15, 2013Phase 2 study in Kidney Failure, ChronicNCT01964196 · 107 enrolled · Japan
  2. Dec 20, 2013Phase 3 study in Renal Insufficiency, ChronicNCT02021318 · 616 enrolled · Austria, Belarus, Bulgaria and more
  3. Jun 9, 20143 phase 1 studiesNCT02161224, NCT02252731, NCT02161796
  4. Oct 28, 2014Phase 3 study in AnemiaNCT02278341 · 838 enrolled · Belgium, Bulgaria, Croatia and more
  5. Feb 3, 2016Phase 1 study in Healthy VolunteersNCT02693613 · 34 enrolled · Japan
  6. May 19, 20163 phase 3 studiesNCT02780141, NCT02779764, NCT02780726
  7. Jun 16, 2016Phase 1 study in Healthy SubjectsNCT02805374 · 16 enrolled · Japan
  8. Oct 31, 2016Phase 3 study in Hemodialysis Chronic Kidney Disease Patients With AnemiaNCT02952092 · 303 enrolled · Japan
  9. Oct 31, 2016Phase 1 study in Healthy SubjectsNCT02952040 · 18 enrolled · Japan
  10. Nov 11, 2016Phase 1 study in Renal InsufficiencyNCT02965040 · 34 enrolled · Germany, United Kingdom
  11. Nov 13, 2016Phase 3 study in Renal Insufficiency, ChronicNCT02964936 · 100 enrolled · Japan
  12. Dec 8, 2016Phase 3 study in Renal Insufficiency, ChronicNCT02988973 · 334 enrolled · Japan
  13. May 21, 2019Phase 1 study in Healthy Adult SubjectsNCT03960489 · 24 enrolled · Germany
  14. Jul 25, 2023Phase 3 study in Renal Insufficiency, ChronicNCT05970172 · 98 enrolled · Belgium, Croatia, Denmark and more

Ahead

  1. Oct 30, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05970172

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 22 Astellas Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05970172Renal Insufficiency, Chronic · Belgium, Croatia, Denmark and more3Active, not recruitingOct 30, 202798
NCT03960489Healthy Adult Subjects · Germany1CompletedOct 14, 201924
NCT02988973Renal Insufficiency, Chronic · Japan3CompletedSep 13, 2019334
NCT02964936Renal Insufficiency, Chronic · Japan3CompletedAug 15, 2018100
NCT02965040Renal Insufficiency · Germany, United Kingdom1CompletedDec 4, 201734
NCT02952092Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedMar 13, 2018303
NCT02952040Healthy Subjects · Japan1CompletedDec 201618
NCT02805374Healthy Subjects · Japan1CompletedAug 201616
NCT02780726Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedAug 2, 201756
NCT02780141ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedDec 12, 201775
NCT02779764Hemodialysis Patients With Renal Anemia · Japan3CompletedMay 16, 2017164
NCT02693613Healthy Volunteers · Japan1CompletedApr 201634
NCT02278341Anemia · Belgium, Bulgaria, Croatia and more3CompletedJun 8, 2017838
NCT02252731Pharmacokinetics of FG-4592 · Germany1CompletedNov 201322
NCT02161796PK for FG-4592 · Germany1CompletedDec 201348
NCT02161224Hepatic Insufficiency · Bulgaria1CompletedDec 201316
NCT02021318Renal Insufficiency, Chronic · Austria, Belarus, Bulgaria and more3CompletedMar 23, 2018616
NCT01964196Kidney Failure, Chronic · Japan2CompletedJul 6, 2015107
NCT01888445Kidney Failure, Chronic · Japan2CompletedSep 15, 2014130
NCT01887600Anemia · Belarus, Belgium, Bulgaria and more3CompletedNov 1, 2017594
NCT01083888Anemia · Japan1CompletedJun 7, 201012
NCT00978198Healthy Volunteers · Japan1CompletedJun 2010100

How it is read

Names in the registry

  • “Roxadustat”, 25 entries
  • “FG-4592”, 9 entries
  • “roxadustat”, 8 entries
  • “ASP1517”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.